Adicet Bio, Inc. Share-based Payment Arrangement, Expense
Adicet Bio, Inc. (ACET) reported Share-based Payment Arrangement, Expense of $1.44 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-05
- Adicet Bio, Inc. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $1.44M, a 50.45% decline year-over-year.
- Adicet Bio, Inc. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $1.30M, a 59.03% decline year-over-year.
- Adicet Bio, Inc. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $5.65M, a 49.75% increase year-over-year.
- Adicet Bio, Inc. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $2.53M, a 62.68% decline year-over-year.
- Adicet Bio, Inc. share-based payment arrangement, expense for fiscal 2025 was $14.27M, a 35.83% decline from fiscal 2024.
- Adicet Bio, Inc. share-based payment arrangement, expense for fiscal 2024 was $22.23M, a 9.74% increase from fiscal 2023.
- Adicet Bio, Inc. share-based payment arrangement, expense for fiscal 2023 was $20.26M, a 18.29% increase from fiscal 2022.
- Adicet Bio, Inc. share-based payment arrangement, expense for fiscal 2022 was $17.13M, a 36.89% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.44M 10-Q · filed 2026-08-05 | $2.74M 10-Q · filed 2026-08-05 | $8.39M derived: sum of 3 quarters · filed 2026-08-05 | $10.92M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $1.30M 10-Q · filed 2026-05-13 | $6.95M derived: sum of 2 quarters · filed 2026-05-13 | $9.48M derived: sum of 3 quarters · filed 2026-05-13 | $12.39M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $5.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $8.18M derived: sum of 2 quarters · filed 2026-03-12 | $11.09M derived: sum of 3 quarters · filed 2026-08-05 | $14.27M 10-K · filed 2026-03-12 |
| 2025-09-30 | $2.53M 10-Q · filed 2025-11-05 | $5.44M derived: sum of 2 quarters · filed 2026-08-05 | $8.62M 10-Q · filed 2025-11-05 | $12.39M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $2.91M 10-Q · filed 2026-08-05 | $6.09M 10-Q · filed 2026-08-05 | $9.86M derived: sum of 3 quarters · filed 2026-08-05 | $16.64M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $3.18M 10-Q · filed 2026-05-13 | $6.95M derived: sum of 2 quarters · filed 2026-05-13 | $13.73M derived: sum of 3 quarters · filed 2026-05-13 | $19.73M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $3.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $10.55M derived: sum of 2 quarters · filed 2026-03-12 | $16.55M derived: sum of 3 quarters · filed 2026-03-12 | $22.23M 10-K · filed 2026-03-12 |
| 2024-09-30 | $6.78M 10-Q · filed 2025-11-05 | $12.78M derived: sum of 2 quarters · filed 2025-11-05 | $18.46M 10-Q · filed 2025-11-05 | $23.37M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $6.00M 10-Q · filed 2025-08-07 | $11.68M 10-Q · filed 2025-08-07 | $16.59M derived: sum of 3 quarters · filed 2025-08-07 | $22.15M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $5.68M 10-Q · filed 2025-05-06 | $10.59M derived: sum of 2 quarters · filed 2025-05-06 | $16.15M derived: sum of 3 quarters · filed 2025-05-06 | $21.17M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $4.91M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $10.47M derived: sum of 2 quarters · filed 2025-03-06 | $15.49M derived: sum of 3 quarters · filed 2025-03-06 | $20.26M 10-K · filed 2025-03-06 |
| 2023-09-30 | $5.56M 10-Q · filed 2024-11-06 | $10.58M derived: sum of 2 quarters · filed 2024-11-06 | $15.35M 10-Q · filed 2024-11-06 | $19.60M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $5.02M 10-Q · filed 2024-08-13 | $9.79M 10-Q · filed 2024-08-13 | $14.04M derived: sum of 3 quarters · filed 2024-08-13 | $18.23M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $4.76M 10-Q · filed 2024-05-14 | $9.02M derived: sum of 2 quarters · filed 2024-05-14 | $13.21M derived: sum of 3 quarters · filed 2024-05-14 | $17.54M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $4.25M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $8.44M derived: sum of 2 quarters · filed 2024-03-19 | $12.78M derived: sum of 3 quarters · filed 2024-03-19 | $17.13M 10-K · filed 2024-03-19 |
| 2022-09-30 | $4.19M 10-Q · filed 2023-11-08 | $8.53M derived: sum of 2 quarters · filed 2023-11-08 | $12.88M 10-Q · filed 2023-11-08 | $17.16M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $4.33M 10-Q · filed 2023-08-09 | $8.69M 10-Q · filed 2023-08-09 | $12.96M derived: sum of 3 quarters · filed 2023-08-09 | $15.49M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $4.35M 10-Q · filed 2023-05-09 | $8.63M derived: sum of 2 quarters · filed 2023-05-09 | $11.16M derived: sum of 3 quarters · filed 2023-05-09 | $13.82M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $4.28M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $6.81M derived: sum of 2 quarters · filed 2023-03-15 | $9.47M derived: sum of 3 quarters · filed 2023-03-15 | $12.51M 10-K · filed 2023-03-15 |
| 2021-09-30 | $2.53M 10-Q · filed 2022-11-08 | $5.19M derived: sum of 2 quarters · filed 2022-11-08 | $8.23M 10-Q · filed 2022-11-08 | $9.88M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $2.66M 10-Q · filed 2022-08-10 | $5.70M 10-Q · filed 2022-08-10 | $7.35M derived: sum of 3 quarters · filed 2022-08-10 | $10.31M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $3.04M 10-Q · filed 2022-05-12 | $4.69M derived: sum of 2 quarters · filed 2022-05-12 | $7.66M derived: sum of 3 quarters · filed 2022-05-12 | $8.01M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $1.65M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $4.61M derived: sum of 2 quarters · filed 2022-03-15 | $4.96M derived: sum of 3 quarters · filed 2022-03-15 | $5.26M 10-K · filed 2022-03-15 |
| 2020-09-30 | $2.97M 10-Q · filed 2021-11-10 | $3.32M derived: sum of 2 quarters · filed 2021-11-10 | $3.62M 10-Q · filed 2021-11-10 | $3.93M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $351.00K 10-Q · filed 2021-08-12 | $650.00K 10-Q · filed 2021-08-12 | $960.00K derived: sum of 3 quarters · filed 2021-08-12 | $1.35M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $299.00K 10-Q · filed 2021-05-17 | $609.00K derived: sum of 2 quarters · filed 2021-05-17 | $1.00M derived: sum of 3 quarters · filed 2021-05-17 | |
| 2019-12-31 | $310.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $701.00K derived: sum of 2 quarters · filed 2021-03-12 | $1.18M 10-K · filed 2021-03-12 | |
| 2019-09-30 | $391.00K 10-Q · filed 2020-11-05 | $865.00K 10-Q · filed 2020-11-05 | ||
| 2018-12-31 | $2.48M 10-K · filed 2021-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |